Skip to Main Content

Peter M. Glazer, MD, PhD

DownloadHi-Res Photo

About

Titles

Robert E. Hunter Professor of Therapeutic Radiology and Professor of Genetics

Chair, Therapeutic Radiology

Biography

Radiation oncologist Peter M. Glazer, MD, PhD, is the chair of the Department of Therapeutic Radiology. He has dedicated his career to helping cancer patients receive the highest quality of care available in a supportive environment.

“When patients are undergoing radiotherapy for cancer, it can be a sensitive and challenging time for them and their families,” he says. “Our team does everything possible to keep our patients safe and comfortable throughout treatment.”

Dr. Glazer makes it his priority to provide patients seeking care at Smilow Cancer Hospital and its Care Centers with the most advanced technologies and evidence-based treatments. “We take great pride in giving our physicians the best tools to treat cancer,” he says.

As a professor of both therapeutic radiology and genetics at Yale School of Medicine, Dr. Glazer researches new therapeutic strategies for treating cancer and the role of altered DNA repair in tumor progression. His research was recently recognized by the National Cancer Institute of the NIH with a prestigious Outstanding Investigator Award of $7 million that will support his efforts to develop novel DNA repair inhibitors for cancer therapy.

Appointments

Education & Training

Resident
Yale-New Haven Hospital (1991)
PhD
Yale University (1987)
MD
Yale University (1987)
MSc
University of Oxford, Biochemistry (1981)
BA
Harvard University, Chemistry (1979)

Research

Overview

Novel pathways that regulate the DNA damage response. Recently, in collaborative work with the Bindra lab, we discovered that the oncometabolite, 2-hydroxyglutarate, generated by neomorphic IDH mutations in gliomas and other maligancies suppresses homologous recombination and confers PARP inhibitor sensitivity, identifying a new approach to treat these malignancies (Sulkowski, Science Translational Medicine, 2017). Similarly, we found that elevated level of the Krebs cycle intermediates, fumarate and succinate, associated with the hereditary cancer syndromes, Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) and Succinate Dehydrogenase-related Hereditary Paraganglioma and Pheochromocytoma (SDH PGL/PCC), also suppress the homologous recombination pathway, rendering these tumors vulnerable to synthetic lethal targeting with PARP inhibitors, pointing to a new therapeutic approach for advanced HLRCC and SDH PGL/PCC, both incurable when metastatic (Sulkowski, Nature Genetics, 2018). The use of PARP inhibitors in these malignancies is currently being tested in several clinical trials directly based on our work. Mechanistically, we determined that oncometabolites suppress homology dependent repair (HDR) by inhibiting the histone lysine demethylase, KDM4B. This causes aberrant hypermethylation of H3K9 across the genome and thereby disrupts the normal temporal and spatial pattern of HDR factor recruitment to sites of DNA DSBs (Sulkowski, Nature, 2020). We also recently characterized a novel pathway by which mitochondrial DNA damage mediates signaling to upregulate nuclear DNA repair (Wu, Nature Metabolism, 2019).

Novel approaches to cancer therapy. Effective cancer treatment depends on achieving a therapeutic window in which there is greater toxicity to the malignant cells than to normal, healthy tissue. We have sought to exploit synthetic lethality by seeking agents that are more toxic to cancer cells deficient in homology-dependent DNA repair. This applies to cancers with genetic defects in genes such as BRCA1, BRCA2, PALB2, and PTEN. But it also applies to hypoxic cancer cells in which there is down-regulation of the HDR genes, BRCA1 and RAD51. Our efforts in this area have focused on a novel lupus-derived, cell-penetrating antibody that functions as a DNA repair inhibitor to radiosensitize cells (Hansen, Science Translational Medicine 2012) and a promising class of natural products (Colis, Nature Chemistry 2014). We have also sought to exploit the acidic tumor microenvironment using a novel pH-dependent trans-membrane delivery peptide (pHLIP) to introduce anti-microRNA peptide nucleic acids (PNAs) antisense agents to disrupt oncomiR addiction (Cheng, Nature 2015). We recently applied this approach to deliver antisense PNAs to inhibit the otherwise undruggable DNA repair factor, Ku80, to sensitize tumors to radiation (Kaplan, Molecular Cancer Research, 2020). Recently, we have shown that the anti-angiogenic agent, cediranib, not only damages tumors by interrupting their blood supply and thereby inducing hypoxia but also directly down-regulates DNA repair, sensitizing cancer cells to PARP inhibitors and suggesting a strategy for targeted treatment that is currently being pursued in several clinical trials at Yale and elsewhere (Kaplan, Science Translational Medicine, 2019).

Hypoxia causes genetic instability, down-regulates DNA repair, and promotes gene silencing. In the mid 1990's, we developed the hypothesis that the hypoxic tumor microenvironment could be a cause of genetic instability in cancer. This was contrary to the dogma at the time, because it was thought that under hypoxia there would be less oxidative damage to DNA. We showed that growth of cancer cells in vivo in tumor xenografts produces an elevated mutation rate compared to growth of the same cells in culture (Reynolds, Cancer Res. 1996), and we went on to demonstrate that this effect could be attributed to hypoxia. Since then, we have systematically dissected the mechanisms underlying this effect. These mechanisms include transcriptional downregulation of the homology-dependent repair genes RAD51 and BRCA1 (Bindra, Cancer Res. 2006), of the Fanconi pathway gene FANCD2(Scanlon, Molecular Cancer Res. 2014) and of the mismatch repair gene, MLH1 (Mihaylova, Mol. Cell. Biol. 2003) plus induction of microRNAs 210 and 373 that suppress expression of several DNA repair factors (Crosby, Cancer Res. 2009). In addition, besides acute transcriptional downregulation, our laboratory discovered that hypoxia promotes silencing of the DNA repair genes, BRCA1 and MLH1, in a pathway that is dependent on the histone lysine demethylase, LSD-1 (Lu, Mol. Cell. Biol. 2011 and Lu, Cell Reports 2014).

Triplex DNA provokes DNA repair, and triplex-forming oligonucleotides can stimulate site-specific gene editing in vivo. In the early 1990's, triplex-forming oligonucleotides (TFOs) were being touted as tools to suppress gene expression by binding to promoter sites to block transcription factor access. However, I realized that the site-specific binding properties of TFOs could also be used to mediate sequence-specific gene editing. We discovered that triplex formation, itself, constitutes a helical alteration sufficient to induce DNA repair at the site of the triplex (Wang, Science 1996 and Vasquez, Science 2000), via the nucleotide excision repair (NER) pathway. This activates the target site for recombination with "donor DNAs" via homology-dependent repair. After a systematic evaluation of DNA analogs for improved triple helix formation in cells, we have focused on peptide nucleic acids (PNAs), which have a neutral polyamide backbone and bind DNA with high affinity. Using PNAs, we demonstrated successful editing of the beta-globin gene in human primary hematopoietic stem cells. In collaboration with the Saltzman lab, we developed a strategy to encapsulate the PNAs and donor DNAs in polymer-based, biocompatible nanoparticles to achieve effective in vivo delivery in mice with minimal toxicity. Recent work with the Egan lab has demonstrated the ability of nanoparticles containing PNAs and donor DNAs to mediate editing of the F508del CFTR gene mutation in airway epithelia in vivo in a mouse model of cystic fibrosis (McNeer, Nature Communications 2015) and to mediate substantial correction of anemia and in mice with thalassemia by simple intravenous injection of PNA and DNA containing nanoparticles in adult mice (Bahal, Nature Communications 2016) and in fetal mice via in utero injection (Ricciardi, Nature Communications, 2018).

Medical Subject Headings (MeSH)

DNA Repair; Gene Editing; Gene Targeting; Genetics; Radiation; Radiation Oncology; Recombinational DNA Repair

Research at a Glance

Yale Co-Authors

Frequent collaborators of Peter M. Glazer's published research.

Publications

2024

2023

2022

Academic Achievements & Community Involvement

  • honor

    Elected to the National Academy of Medicine 2022

Clinical Care

Overview

Radiation oncologist Peter M. Glazer, MD, PhD, is the chair of the Department of Therapeutic Radiology. He has dedicated his career to helping cancer patients receive the highest quality of care available in a supportive environment.

“When patients are undergoing radiotherapy for cancer, it can be a sensitive and challenging time for them and their families,” he says. “Our team does everything possible to keep our patients safe and comfortable throughout treatment.”

Dr. Glazer makes it his priority to provide patients seeking care at Smilow Cancer Hospital and its Care Centers with the most advanced technologies and evidence-based treatments. “We take great pride in giving our physicians the best tools to treat cancer,” he says.

As a professor of both therapeutic radiology and genetics at Yale School of Medicine, Dr. Glazer researches new therapeutic strategies for treating cancer and the role of altered DNA repair in tumor progression. His research was recently recognized by the National Cancer Institute of the NIH with a prestigious Outstanding Investigator Award of $7 million that will support his efforts to develop novel DNA repair inhibitors for cancer therapy.

Clinical Specialties

Therapeutic Radiology

Board Certifications

  • Radiation Oncology

    Certification Organization
    AB of Radiology
    Original Certification Date
    1992

Get In Touch

Contacts

Academic Office Number
Office Fax Number
Mailing Address

Therapeutic Radiology

PO Box 208040

New Haven, CT 06520-8040

United States

Administrative Support

Locations

  • Patient Care Locations

    Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.